Skip to main content

Table 2 Comparison of clinicopathological characteristics before and after PSM in neoadjuvant group

From: Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study

Patient Characteristics Unmatched comparison Matched comparison
Patients with NEC components (n = 63) Gastric adenocarcinoma (n = 477) P value Patients with NEC components (n = 60) Gastric adenocarcinoma (n = 120) P value
Age (year), mean ± SD 61.2 ± 9.6 58.3 ± 10.3 0.037 61.3 ± 9.7 60.2 ± 9.5 0.484
Gender (male/female) 52/11 367/110 0.316 50/10 104/16 0.549
BMI, mean ± SD 24.1 ± 3.9 23.5 ± 3.4 0.285 23.9 ± 3.9 23.8 ± 3.4 0.855
Adjuvant therapy    0.124    0.173
 Yes 58 (92.1) 459 (96.2)   56 (93.9) 117 (97.5)  
 No 5 (7.9) 18 (3.8)   4 (6.7) 3 (2.5)  
Tumor location    < 0.001    0.361
 Upper third 46 (73.0) 222 (46.5)   43 (71.7) 79 (65.8)  
 Middle third 9 (14.3) 50 (10.5)   9 (15.0) 13 (10.8)  
 Lower third 7 (11.1) 189 (39.6)   7 (11.7) 21 (17.5)  
 Entire 1 (1.6) 16 (3.4)   1 (1.7) 7 (5.8)  
Tumor size    0.325    0.594
 < 5 cm 36 (57.1) 303 (63.5)   33 (55.0) 71 (59.2)  
 ≥ 5 cm 27 (42.9) 174 (36.5)   27 (45.0) 49 (40.8)  
Type of gastrectomy    < 0.001    0.974
 Total gastrectomy 50 (79.4) 239 (50.1)   47 (78.3) 94 (78.3)  
 Distal gastrectomy 7 (11.1) 181 (37.9)   7 (11.7) 15 (12.5)  
 Proximal gastrectomy 6 (9.5) 57 (11.9)   6 (10.0) 11 (9.2)  
Surgical procedure    0.394    1.000
 Open 60 (95.2) 440 (92.2)   57 (95.0) 114 (95.0)  
 Laparoscopic 3 (4.8) 37 (7.8)   3 (5.0) 6 (5.0)  
T stage    < 0.001    0.065
 T0 1 (1.6) 0 (0.0)   0 (0.0) 0 (0.0)  
 T1 3 (4.8) 28 (5.9)   3 (5.0) 3 (2.5)  
 T2 3 (4.8) 60 (12.6)   3 (5.0) 15 (12.5)  
 T3 35 (55.6) 154 (32.3)   34 (56.7) 47 (39.2)  
 T4 21 (33.3) 235 (49.6)   20 (33.3) 55 (45.8)  
N stage    0.017    0.186
 N0 17 (27.0) 158 (33.1)   16 (26.7) 44 (36.7)  
 N1 22 (34.9) 99 (20.8)   21 (35.0) 33 (27.5)  
 N2 14 (22.2) 80 (16.8)   14 (23.3) 17 (14.2)  
 N3 10 (15.9) 140 (29.4)   9 (15.0) 26 (21.7)  
M stage    0.041    0.721
 M0 60 (95.2) 471 (98.7)   59 (98.3) 117 (97.5)  
 M1 3 (4.8) 6 (1.3)   1 (1.7) 3 (2.5)  
ypTNM stage    0.001    0.950
 0 1 (1.6) 0 (0.0)   0 (0.0) 0 (0.0)  
 I 4 (6.3) 52 (10.9)   4 (6.7) 6 (5.0)  
 II 31 (49.2) 163 (34.2)   31 (51.7) 64 (53.3)  
 III 24 (38.1) 256 (53.7)   24 (40.0) 47 (39.2)  
 IV 3 (4.8) 6 (1.3)   1 (1.7) 3 (2.5)  
  1. BMI Body Mass Index, MiNEN Mixed neuroendocrine-non-neuroendocrine neoplasm, NEC neuroendocrine carcinoma, PSM Propensity Score Matching
  2. Patients with NEC components: NEC, < 30% high grade MiNEN, high grade MiNEN and > 70% high grade MiNEN